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ffects of Normal, Pre-Hypertensive,
nd Hypertensive Blood Pressure Levels
n Progression of Coronary Atherosclerosis
lke Sipahi, MD,* E. Murat Tuzcu, MD, FACC,* Paul Schoenhagen, MD,† Katherine E. Wolski, MPH,*
tephen J. Nicholls, MBBS, PHD, FACC,* Craig Balog, BS,* Timothy D. Crowe, BS,*
teven E. Nissen, MD, FACC*
leveland, Ohio
OBJECTIVES The purpose of this study was to evaluate the effects of normal blood pressure (BP),
pre-hypertension, and hypertension on progression of coronary atherosclerosis.
BACKGROUND The Seventh Report of the Joint National Committee on the Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC-7) classifies BP as normal,
pre-hypertension, and hypertension. The effects of these categories on progression of
coronary atherosclerosis are unknown.
METHODS The 274 patients who completed the intravascular ultrasound (IVUS) substudy of the
CAMELOT (Comparison of Amlodipine Versus Enalapril to Limit Occurrences of
Thrombosis) trial were included. The entry criteria were 1 angiographic coronary stenosis
20% and diastolic BP 100 mm Hg. Patients underwent a baseline coronary IVUS, which
was repeated after 2 years of amlodipine, enalapril, or placebo therapy. The BP was evaluated
periodically, and the averages of the measurements were used in the analyses.
RESULTS Mean BP throughout the study was 127.0  12.0/75.5  6.8 mm Hg. In multivariable
analysis, significant determinants of progression included systolic BP (r  0.16; p  0.006)
and pulse pressure (r  0.14; p  0.02). Patients with “hypertensive” average BP had a 12.0
 3.6 mm3 (least-square mean  SE) increase in atheroma volume, those with “pre-
hypertensive” BP had no major change (0.9  1.8 mm3), and those with “normal” BP had a
decrease of 4.6  2.6 mm3 (p  0.001 by analysis of covariance; p  0.05 for comparison of
all pairs).
CONCLUSIONS The most favorable rate of progression of coronary atherosclerosis is observed in patients
whose BP falls within the “normal” JNC-7 category (i.e., systolic BP 120 mm Hg and
diastolic BP 80 mm Hg). This study suggests that in patients with coronary artery disease,
the optimal BP goal may be substantially lower than the140/90 mm Hg level. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.045Cardiol 2006;48:833–8) © 2006 by the American College of Cardiology Foundation
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pypertension is an extremely common disease, affecting
pproximately 1 billion people worldwide (1). The Seventh
eport of the Joint National Committee on Prevention,
etection, Evaluation, and Treatment of High Blood Pres-
ure (JNC-7), defined a new entity, “pre-hypertension,” to
See page 839
eflect the growing evidence that systolic blood pressure
SBP) values between 120 and 139 mm Hg and diastolic
lood pressure (DBP) values between 80 and 89 mm Hg are
ssociated with increased cardiovascular risk (2). It is esti-
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ccepted May 15, 2006.ated that an additional 30% of the adult population fall
nto this category (3). However, few clinical trials have
xamined patients with blood pressure (BP) levels in the
re-hypertensive range, precluding any definitive recom-
endations for the treatment of this population. Therefore,
n JNC-7, the therapeutic BP target for the general popu-
ation remained at 140/90 mm Hg.
Coronary artery disease is the most common form of
arget-organ damage and most common cause of mortality
ssociated with hypertension. Although several studies have
xamined the relationship between hypertension on coro-
ary events, and some have extended these observations to
he “pre-hypertension” range (4), no prior data exist regard-
ng the impact of hypertension, pre-hypertension, and
ormal BP on progression of coronary atherosclerosis.
ecently, intravascular ultrasound (IVUS) has been used
uccessfully to study the effects of drug therapies on pro-
ression of coronary disease, including agents that reduce
ow-density lipoprotein (LDL) cholesterol and C-reactive
rotein or modulate high-density lipoprotein (HDL) cho-esterol (5–7). Although invasive, IVUS permits precise
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Blood Pressure and Coronary Disease Progression August 15, 2006:833–8easurement of atheroma burden at baseline and follow-up,
nabling calculation of progression rate of atherosclerosis.
he CAMELOT (Comparison of Amlodipine Versus
nalapril to Limit Occurrences of Thrombosis) trial en-
olled coronary disease patients with a mean BP of 129/78
m Hg and included an IVUS substudy that assessed the
hange in atherosclerotic disease burden during the 2-year
ollow-up (8). In the present analysis, our objective was to
xamine the effects of components of BP (SBP, DBP, and
ulse pressure) and the JNC-7 BP categories on coronary
isease progression in the CAMELOT trial.
ETHODS
tudy population. The CAMELOT trial was a multi-
enter double-blinded randomized trial that compared the
ffects of amlodipine up to 10 mg/day versus enalapril up to
0 mg/day versus placebo on cardiovascular event rates in
atients with coronary artery disease (8). The study enrolled
en and women age 30 to 79 years who required coronary
ngiography for clinical indications and demonstrated at
east 1 obstruction with angiographic diameter stenosis of
20%. Study eligibility required a DBP100 mm Hg with
r without treatment. There were 1,997 patients enrolled in
he CAMELOT trial, and 274 of them completed the
VUS substudy. The Cleveland Clinic Institutional Review
oard approved research using this database.
VUS. Subjects enrolled in the IVUS substudy underwent a
aseline ultrasound interrogation before randomization.
he acquisition and measurement methodology of IVUS
therosclerosis progression-regression trials have been de-
cribed in detail elsewhere (6,7). Briefly, after administra-
ion of intracoronary nitroglycerin, the IVUS catheter was
dvanced into the target vessel and the transducer was
ositioned distal to a side branch (distal fiduciary site). The
arget vessel for the IVUS interrogation (a single coronary
rtery per patient) must not have undergone percutaneous
ntervention or have an angiographic diameter stenosis of
50%. A motor drive unit progressively withdrew the
ransducer at a speed of 0.5 mm/s. During pullback, images
Abbreviations and Acronyms
BP  blood pressure
CAMELOT  Comparison of Amlodipine Versus
Enalapril to Limit Occurrences of
Thrombosis trial
DBP  diastolic blood pressure
HDL  high-density lipoprotein
IVUS  intravascular ultrasound
JNC-7  Seventh Report of the Joint National
Committee on Prevention, Detection,
Evaluation, and Treatment of High
Blood Pressure
LDL  low-density lipoprotein
LOWESS  locally weighted scatterplot smoothing
SBP  systolic blood pressureere obtained at 30 frames/s and were recorded on video- pape for off-line analysis. After digitization of the video-
apes, measurements of external elastic membrane (EEM)
nd lumen areas were performed in accordance with the
tandards of the American College of Cardiology (9).
easurements were performed at every 60th frame (i.e.,
very 1 mm) starting at the distal branch site and ending at
proximal branch site. Follow-up IVUS was performed in
he same arterial segments after a 24-month treatment
egimen consisting of amlodipine, enalapril, or placebo.
alculation of end points. Atheroma volume was calcu-
ated as: (EEM area  lumen area), which corresponded
o the sum of the atheroma areas in slices spaced 1 mm
part. To compensate for pullbacks of differing lengths,
normalized atheroma volume” was used in the analyses,
alculated as:
 atheroma volumenumber of measured imagesmean number of imagesfor all pullbacks
P and lipid profile measurements. The BP was mea-
ured at baseline, at the first month, and every 3 months
hereafter. Measurements were taken after the patient had
een seated for 3 min and then repeated 2 min later. The 2
alues were averaged at each visit. Pulse pressure was
alculated as: SBP  DBP. For each BP component, the
ean value observed throughout the study period was
alculated by averaging the values obtained at each visit
xcept the baseline visit. The BP was categorized as “hy-
ertensive” if mean SBP was 140 mm Hg or mean DBP
as 90 mm Hg, as “pre-hypertensive” if mean SBP was
20 to 139 mm Hg or mean DBP was 80 to 89 mm Hg, and
s “normal” if mean SBP was120 mm Hg and mean DBP
as 80 mm Hg (2). A central laboratory measured the
ipid profile at baseline and every 6 months, and mean lipid
evels throughout the study were calculated in a similar
ashion to the mean BP.
ata analysis. Analyses were performed with SPSS 11.5
or Windows (SPSS Inc., Chicago, Illinois). General char-
cteristics of patients are summarized using mean  SD for
ontinuous data and number (%) for categorical data.
aseline and follow-up IVUS data are presented as mean 
D and median (interquartile range) owing to the non-
ormal distribution of these variables. Relationships were
ssessed by multiple linear regression analysis and partial
orrelation coefficients were obtained. Since many variables
e.g., atheroma volumes, lipid parameters, pulse pressure)
ere not normally distributed, rank transformed data were
sed in the regression analyses. For plotting the relation-
hips between BP and change in atheroma volume, locally
eighted scatterplot smoothing (LOWESS) technique was
sed. For comparing the baseline atheroma volume among
he JNC-7 BP categories, the nonparametric Kruskal-
allis test was used. Analysis of covariance was used to
xamine the impact of the JNC-7 BP categories on the
rogression rate, and least-square means  SE were ob-
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August 15, 2006:833–8 Blood Pressure and Coronary Disease Progressionained. Pair-wise comparisons between the 3 JNC-7 cate-
ories were not adjusted for multiple comparisons. Two-
ided p values of 0.05 were considered significant.
ESULTS
tudy population. In the total study population of 274
atients, the baseline BP was similar to the full CAM-
LOT trial cohort: 129.9  15.6/77.2  8.4 mm Hg.
ecause about two-thirds of the patients were on active
reatment arms, BP was significantly decreased at the
4-month follow-up: 126.2  15.8/75.1  10.2 mm Hg.
ean on-treatment BP throughout the study period was
27.0  12.0/75.5  6.8 mm Hg.
According to the classification criteria of the JNC-7, 76
atients (27.7%) had mean on-treatment BP levels within
he normal range (on average 114/71 mm Hg), 157 (57.3%)
ithin the pre-hypertensive range (on average 128/76 mm
g), and 41 (15%) within the hypertensive range (on
verage 147/80 mm Hg). The characteristics of patients
ith normal, pre-hypertensive, and hypertensive BP levels
re presented in Table 1. Patients with higher BP levels
ere older, more likely to be female, and, predictably, more
ikely to have a history of hypertension. Patients with lower
lood pressure levels showed trends for having higher
DL/HDL cholesterol ratios and higher triglyceride levels.
atients with lower average BP levels were more commonly
llocated to the active treatment arms consisting of amlo-
ipine and enalapril. The frequency of concomitant statin
reatment was similar among the 3 categories.
eterminants of progression of coronary artery disease.
here was no relationship between age, gender, body mass
able 1. Characteristics of Patients With Normal, Pre-Hypertensive
Characteristic
Normal
(n  76)
ge, yrs 53.0  8.4
ale 65 (85.5%)
ody mass index, kg/m2 29.4  4.4
urrent smoker 19 (25.0%)
istory of hypertension 33 (43.4%)
istory of diabetes 10 (13.1%)
ipid profile†
Total cholesterol, mg/dl 183.2  27.6
LDL cholesterol, mg/dl 100.0  22.2
HDL cholesterol, mg/dl 41.1  11.1
Triglycerides, mg/dl 194.1  97.3
LDL/HDL cholesterol ratio 2.6  0.8
tudy medications
Amlodipine 26 (34.2%)
Enalapril 33 (43.4%)
Placebo 17 (22.3%)
oncomitant medications
Aspirin 75 (98.6%)
Beta-blocker 57 (75.0%)
Statin 66 (86.8%)
p values for continuous variables were obtained with analysis of variance except for
he p values for categorical variables were obtained with the chi-square test; †averag
HDL  high-density lipoprotein; LDL  low-density lipoprotein.ndex, current smoking status, diabetes, and change in atheroma volume (Table 2). Total cholesterol, LDL cho-
esterol, and triglycerides trended toward a positive correla-
ion and HDL cholesterol toward a negative correlation
ith change in atheroma volume. The LDL/HDL choles-
erol ratio was the strongest determinant of change in
theroma volume (r  0.18; p  0.003).
Among components of BP, mean SBP correlated
ignificantly with change in atheroma volume (r  0.14;
 0.02). There was no significant relationship between
Hypertensive Average Blood Pressure Levels During the Study
re-Hypertensive
(n  157)
Hypertensive
(n  41) p Value*
57.5  9.4 61.9  10.5 0.001
123 (78.3%) 27 (65.8%) 0.047
30.2  4.8 31.3  6.3 0.15
37 (23.5%) 9 (21.9%) 0.90
110 (70.0%) 32 (78.0%) 0.001
31 (19.7%) 6 (14.6%) 0.41
179.9  34.7 173.7  41.1 0.35
98.2  27.8 94.6  37.4 0.64
41.2  11.7 44.4  14.7 0.28
185.9  118.1 170.5  95.1 0.13
2.6  1.1 2.2  0.8 0.07
0.02
56 (35.6%) 9 (21.9%)
42 (26.7%) 13 (31.7%)
59 (38.0%) 19 (46.3%)
150 (95.5%) 38 (92.6%) 0.26
134 (85.3%) 34 (82.9%) 0.15
140 (89.1%) 34 (82.9%) 0.54
erides and LDL/HDL cholesterol ratio for which the Kruskal-Wallis test was used.
es during the study period.
able 2. Relationships Between Patient Characteristics and
hange in Atheroma Volume*
Correlation
Coefficient p Value
ge 0.04 0.53
ale gender 0.004 0.95
ody mass index 0.02 0.69
urrent smoking 0.02 0.81
istory of hypertension 0.12 0.05
istory of diabetes 0.06 0.35
ipid profile
Total cholesterol 0.10 0.11
LDL cholesterol 0.10 0.09
HDL cholesterol 0.11 0.07
Triglycerides 0.11 0.06
LDL/HDL cholesterol ratio 0.18 0.003
P components
SBP 0.14 0.02
DBP 0.09 0.15
Pulse pressure 0.11 0.06
Based on rank transformed data and adjusted for baseline atheroma volume. For lipid
arameters and blood pressure components, average values throughout the study
eriod were used. Since 2 patients had incomplete laboratory data, the results of 272
atients are shown for the lipid parameters., and
P
triglycDBP diastolic blood pressure; SBP systolic blood pressure; other abbreviations
s in Table 1.
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Blood Pressure and Coronary Disease Progression August 15, 2006:833–8BP and change in atheroma volume (r  0.09; p 
.15). Figure 1 shows the LOWESS graph for the
elationship between SBP and progression rate of coro-
ary atherosclerosis.
Multivariable analysis was performed to control for pos-
ible confounding variables. Mean on-treatment LDL/
DL cholesterol ratio and triglycerides were included in
hese models because they were related to both the predictor
ariable (BP) and the outcome variable (disease progres-
ion). In this type of analysis, mean SBP remained as a
ignificant predictor of change in atheroma volume (r 
.16; p  0.006) (Table 3). There was still no significant
elationship between DBP and change in atheroma volume.
owever, there was a significant correlation between pulse
ressure and change in atheroma volume in multivariable
nalysis.
igure 1. Locally weighted scatterplot smoothing graph showing the
elationships between systolic blood pressure (SBP) and the rate of
rogression of coronary atherosclerosis (n  274). An SBP in the range of
pproximately 120 to 140 mm Hg corresponded to no net progression or
egression of coronary disease. Values above this range were associated with
rogression and those below were associated with regression of disease.
able 4. Intravascular Ultrasonographic Measures of Atheroma B
ypertensive Average Blood Pressure Levels During the Study
Normal
(n  76)
aseline atheroma volume (mm3)
Mean  SD 187.9  79.5
Median (interquartile range) 180.8 (133.1–238.1)
ollow-up atheroma volume (mm3)
Mean  SD 184.5  74.6
Median (interquartile range) 168.2 (129.3–238.4)
p value‡ (compared to baseline) 0.08
hange in atheroma volume (mm3)
Least-square mean  SE 4.6  2.6
Kruskal-Wallis test; †analysis of covariance model with rank-transformed baseline v
odel with rank-transformed LDL/HDL cholesterol ratio and triglycerides as covariare shown.
Abbreviations as in Tables 1 and 2.Although mean on-treatment BP levels significantly cor-
elated with the progression rate, the changes in the BP
omponents from baseline to follow-up did not correlate
ith change in atheroma volume (p  0.30 for all).
NC-7 categories and progression rate. The IVUS find-
ngs of patients with normal, pre-hypertensive, and hyper-
ensive average BP levels are presented in Table 4. There
as no significant difference in the atheroma volumes of the
categories at baseline (p  0.29). However, the progres-
ion rate of atherosclerosis was significantly different among
hese categories (p  0.001 by analysis of covariance).
ccordingly, hypertensive subjects had an increase in ad-
usted atheroma volume of 12.0 mm3 (p  0.001 compared
ith baseline), pre-hypertensive subjects had no major
hange (0.9 mm3; p  0.61 compared with baseline), and
ubjects with normal BP had a decrease in atheroma volume
f 4.6 mm3 (p 0.08 compared with baseline) (p 0.05 for
ll pair-wise comparisons) (Fig. 2). These findings were not
ifferent after additional adjusting for allocation to amlo-
ipine and enalapril arms (p  0.001 by analysis of
ovariance; p  0.05 for all pair-wise comparisons). Addi-
ionally, there was no significant interaction between either
mlodipine or enalapril treatment and the effects of BP
ategories on the progression rate (p  0.20 and p  0.46,
espectively).
There were 42 patients who moved from the pre-
ypertension category at baseline to the normal BP category
uring the study, of which 32 were on an active treatment
able 3. Relationships Between Blood Pressure Components
nd Change in Atheroma Volume on Multivariable Analysis*
Correlation
Coefficient p Value
BP 0.16 0.006
BP 0.08 0.16
ulse pressure 0.14 0.02
Based on rank transformed data and adjusted for baseline atheroma volume,
DL/HDL cholesterol ratio, and triglycerides. For each blood pressure component,
he average value observed throughout the study period was used. Since 2 patients had
ncomplete laboratory data, the results of 272 patients are shown.
Abbreviations as in Tables 1 and 2.
n in Patients With Normal, Pre-Hypertensive, and
Pre-Hypertensive
(n  155)
Hypertensive
(n  41) p Value
190.8  81.6 202.2  61.7 0.29*
171.7 (137.4–241.2) 205.4 (158.7–250.9)
191.7  82.0 211.5  64.7 0.001†
179.5 (133.1–227.3) 212.2 (155.2–259.9)
0.61 0.001
0.9  1.8 12.0  3.6 0.001†
LDL/HDL cholesterol ratio and triglycerides as covariates; ‡analysis of covariance
ince 2 patients had incomplete plasma lipid data, the results of a total of 272 patientsurde
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August 15, 2006:833–8 Blood Pressure and Coronary Disease Progressionrm. In contrast, 121 patients remained in the pre-
ypertension category from baseline to follow-up. The
rogression rate was significantly lower in the group that
ad transition from pre-hypertension to normal BP (6.2 
.6 mm3 [mean  SE] decrease in atheroma volume)
ompared with the group who remained pre-hypertensive
1.5  2.1 mm3 increase in atheroma volume; p  0.037 by
nalysis of covariance).
ISCUSSION
he study demonstrates a continuous relationship between
BP and the progression rate of coronary atherosclerosis
ver a broad range of blood pressures extending from 100
m Hg to the hypertensive range.
Hypertension is usually defined as a systolic pressure
bove 140 mm Hg and/or a diastolic pressure above 90 mm
g. It represents a strong risk factor for coronary and
oncoronary cardiovascular events and mortality. Accumu-
ating evidence has suggested that there is no threshold BP
alue below which cardiovascular risk does not decrease,
ith optimal event rates observed for levels below 115/75
m Hg (4). Consonant with these observations, the World
ealth Organization has reported that a suboptimal BP
i.e., SBP 115 mm Hg) represents the number 1 attrib-
table risk for death throughout the world. In light of this
vidence, the JNC-7 classification of BP introduced a new
ategory called “pre-hypertension” (defined as a systolic
ressure between 120 and 139 mm Hg or a diastolic
ressure between 80 and 89 mm Hg) to emphasize the
ncreased cardiovascular risk and the high likelihood of pro-
igure 2. Progression rate of coronary artery disease according to Seventh
eport of the Joint National Committee on Prevention, Detection,
valuation, and Treatment of High Blood Pressure (JNC 7) blood pressure
ategories. Error bars represent means and 95% confidence intervals. *The
values were obtained using rank transformed data and adjusting for
aseline total atheroma volume, low-density lipoprotein (LDL)/high-
ensity lipoprotein (HDL) cholesterol ratio, and triglycerides. ANCOVA
analysis of covariance.ression to frank hypertension. However, in the absence of candomized clinical trials, JNC-7 recommends only lifestyle
odifications without drug therapy for pre-hypertension, un-
ess the patient has concomitant diabetes or chronic kidney
isease and a blood pressure above 130/80 mm Hg. Likewise,
n other patients with established hypertension, the therapeutic
P goal remains 140/90 mm Hg.
Coronary artery disease is the most common target organ
amage noted as a result of hypertension and the most
mportant cause of mortality in hypertensive patients. The
resent study demonstrates that in patients with coronary
rtery disease and “acceptable” BP levels by current stan-
ards (127/76 mm Hg on average), SBP is still a significant
eterminant of disease progression. Comparison of patients
n the different JNC-7 categories revealed that those with
hypertensive” BP levels have the worst outcome (a 12 mm3
ncrease in atheroma volume on an arterial segment of
pproximately 30 mm in 2 years), those with “pre-
ypertensive” BP have an intermediate outcome (an increase
f 0.9 mm3), and those with “normal” BP have the best
utcome, showing a trend for disease regression (a 4.6 mm3
eduction in atheroma volume). Patients who improved
rom a pre-hypertensive BP level at baseline to normal BP
evels during the study had significantly less progression of
theroma than patients who remained pre-hypertensive.
These findings are consistent with epidemiologic data
emonstrating that coronary event rates are highest in those
ith hypertension, intermediate in those with pre-
ypertension, and lowest in those with normal BP (10,11).
lthough the JNC-7 sets lower BP goals for patients with
iabetes and chronic kidney disease, the target BP levels in
atients with coronary artery disease are not different from
ecommendations for the general population. Our findings
uggest that optimal BP for patients with coronary artery
isease is substantially lower than the 140/90 mm Hg
evel and may be as low as 120/80 mm Hg. Patients
chieving a normal BP (on average 114/71 mm Hg) actually
howed a strong trend toward regression, a finding previ-
usly demonstrated only for aggressive interventions such as
nfusion of an HDL mimetic (7).
The relationship between BP and coronary disease
rogression was independent of the study treatments
onsisting of enalapril, an angiotensin-converting en-
yme inhibitor, and amlodipine, a calcium-channel
locker. This demonstrates that for slowing progression
f coronary atherosclerosis, the absolute BP level attained
s a crucial parameter, regardless of the particular BP-
owering drug used.
The current study adds mechanistic insights regarding
he relationship between BP components and clinical event
ates. Systolic pressure appears to be an important compo-
ent for progression of coronary atherosclerosis. This find-
ng complements the studies reporting on the strong rela-
ionship between SBP and coronary events (12–17). Studies
elating DBP and pulse pressure to cardiovascular event
ates have yielded mixed results (12–15,18–22). In this
ontext, our study specifically excluded patients with a
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Blood Pressure and Coronary Disease Progression August 15, 2006:833–8iastolic pressure 100 mm Hg. Therefore our finding of
o significant relationship between DBP and disease pro-
ression should be interpreted with caution. It is possible
hat higher DBP levels may have a different relationship to
isease progression. Moreover, narrowing the range of DBP
ay have reduced its predictive ability by reducing its
ariance.
tudy limitations. This study examined a group of patients
ith existing coronary disease, not a general hypertensive
opulation. Thus, no conclusion regarding the optimal BP
an be drawn from this study for primary prevention
atients. Most of the enrolled patients were white and
iddle aged. Therefore, our findings may not apply to other
aces or age groups.
onclusions. In a patient population with well controlled
P and coronary artery disease, a higher SBP level is
ssociated with greater progression of coronary atheroscle-
osis. Normal BP (i.e., SBP 120 mm Hg and DBP 80
m Hg) is the most favorable JNC-7 BP category to slow
rogression or induce regression of coronary artery disease.
or secondary prevention of coronary artery disease, the
urrent IVUS study demonstrates that optimal outcomes are
ttained for patients reaching a BP goal substantially lower
han the 140/90 mm Hg level advocated in the current
uidelines.
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